AZ gets China nod for Tagrisso in first-line lung cancer

AstraZeneca gets further approval for Tagrisso in Japan

AstraZeneca received approval from the Japanese regulator following a priority review of Tagrisso (osimertinib) as a first-line treatment of patients with positive non-small cell lung cance

AZ’s Tagrisso wins new NSCLC first-line approval in Europe

AstraZeneca has widened the licence for its cancer drug Tagrisso (osimertinib) in Europe after regulators gave it the green-light for first-line use against additional types of non-small ce

AZ's Tagrisso gets full US approval in lung cancer

Phase 3 data confirmed its efficacy in patients with a certain mutation.